Hyderabad, India and Princeton, NJ, USA. June 25, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today
announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of
TOBI®
(tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
The TOBI®
(tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million
MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.
Dr. Reddy’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 mL, single-dose Ampule.
Tobi®
is a trademark of Mylan.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
